

Interview Summary Okay
EDT 07/06/2005

REMARKS

1. Status of the Claims and Formal Matters

a. Interview Summary

Applicant thanks the Examiner for the courtesy shown during the telephone interview of 30 March 2005, during which the cited art, claim scope, and possible amendments were discussed. The possibility of a declaration from the inventor explaining the use of the name "Isaac" and "Itzak" were also discussed.

b. Declaration of Dr. Isaac Bentwich

The Applicant submits herewith a "Declaration of Isaac Bentwich" in which Dr. Bentwich states that the names "Isaac" and "Itzak" used interchangeable on a number of pending patent applications both refer to him and that "Itzak" is the Hebrew version of "Isaac."

c. Amendments

Claims 1-2 and 5-25 are pending in this application. Claims 2, 5-7, 9-10, 13, 15-22, 24 and 25 are withdrawn from further consideration. Claims 1, 8, 12, and 23 are amended. New claim 26 has been added and is supported in the application as filed. Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application.

d. Information Disclosure Statement

At page 4 of the Office Action, the Examiner states that the references listed in the specification are not a proper information disclosure statement. An Information Disclosure Statement in compliance with 37 CFR §§ 1.56, 1.97 and 1.98 was filed on March 21, 2006. Applicant respectfully requests that the cited references be considered by the Examiner.

e. Co-Pending Applications

In response to the Examiner's instruction that Applicants identify any additional co-pending or related applications that contain claims drawn to a nucleic acid sequence and wherein the disclosure includes a list of SEQ ID NO:14 as listed in the present application. In response, the Applicants have searched for that sequence in copending applications and have found the sequence in U.S. Patent Application Nos. 60/522,459; 10/536,560 as SEQ ID NO:294; 10/536,560 as SEQ ID NOS:14496, 781 AND 782.